Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
The pre-recorded fireside chat will be made available on the Events and Presentations page of CytomX’s website at www.cytomx.com for on-demand viewing starting Monday, September 13, 2021 at 7:00 a.m. ET. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.